{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:56:57Z","timestamp":1784289417010,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Research Project of Huai'an City","award":["HAB2024017"],"award-info":[{"award-number":["HAB2024017"]}]},{"name":"Natural Science Research Project of Huai'an City","award":["HAB2024017"],"award-info":[{"award-number":["HAB2024017"]}]},{"DOI":"10.13039\/501100006606","name":"Tianjin Natural Science Foundation","doi-asserted-by":"crossref","award":["21JCYBJC01020"],"award-info":[{"award-number":["21JCYBJC01020"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["TJYXZDXK-011A"],"award-info":[{"award-number":["TJYXZDXK-011A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-025-02172-2","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:14:42Z","timestamp":1764162882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Machine learning identifies TIME subtypes linking EGFR mutations and immune states in lung adenocarcinoma"],"prefix":"10.1038","volume":"8","author":[{"given":"Zetian","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bicheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongli","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengpeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"2172_CR1","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","volume":"36","author":"S Gettinger","year":"2018","unstructured":"Gettinger, S. et al. Five-year follow-up of nivolumab in previously treated advanced non\u2013small-cell lung cancer: results from the CA209-003 study. J. Clin. Oncol. 36, 1675\u20131684 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2172_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee, H. et al. Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer. N. Engl. J. Med. 389, 491\u2013503 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2172_CR3","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"2172_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41571-023-00844-0","volume":"21","author":"J LoPiccolo","year":"2024","unstructured":"LoPiccolo, J., Gusev, A., Christiani, D. C. & J\u00e4nne, P. A. Lung cancer in patients who have never smoked - an emerging disease. Nat Rev. Clin. Oncol 21, 121\u2013146 (2024).","journal-title":"Nat Rev. Clin. Oncol"},{"key":"2172_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33351-4","volume":"13","author":"F Ma","year":"2022","unstructured":"Ma, F., Laster, K. & Dong, Z. The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. Nat. Commun. 13, 5651 (2022).","journal-title":"Nat. Commun."},{"key":"2172_CR6","first-page":"205","volume":"3","author":"T Mitsudomi","year":"2014","unstructured":"Mitsudomi, T. Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. Transl. Lung Cancer Res. 3, 205\u2013211 (2014).","journal-title":"Transl. Lung Cancer Res."},{"key":"2172_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria, J.-C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2172_CR8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jtho.2016.12.014","volume":"12","author":"E Castellanos","year":"2017","unstructured":"Castellanos, E., Feld, E. & Horn, L. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer. J. Thorac. Oncol. 12, 612\u2013623 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"2172_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","volume":"12","author":"Q Wang","year":"2019","unstructured":"Wang, Q., Yang, S., Wang, K. & Sun, S.-Y. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J. Hematol. Oncol. 12, 63 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2172_CR10","doi-asserted-by":"publisher","first-page":"e003534","DOI":"10.1136\/jitc-2021-003534","volume":"10","author":"L Yang","year":"2022","unstructured":"Yang, L. et al. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma. J. Immunother. Cancer 10, e003534 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2172_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06940-y","volume":"15","author":"M Izumi","year":"2024","unstructured":"Izumi, M. et al. Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer. Cell Death Dis. 15, 580 (2024).","journal-title":"Cell Death Dis."},{"key":"2172_CR12","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1016\/j.jtho.2018.09.012","volume":"13","author":"MI Toki","year":"2018","unstructured":"Toki, M. I. et al. Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations. J. Thorac. Oncol. 13, 1884\u20131896 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"2172_CR13","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian, S. L. et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non\u2013small cell lung cancer treated with nivolumab. JAMA Oncol. 5, 1411\u20131420 (2019).","journal-title":"JAMA Oncol."},{"key":"2172_CR14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","volume":"635","author":"F Skoulidis","year":"2024","unstructured":"Skoulidis, F. et al. CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors. Nature 635, 462\u2013471 (2024).","journal-title":"Nature"},{"key":"2172_CR15","doi-asserted-by":"publisher","first-page":"102179","DOI":"10.1016\/j.ctrv.2021.102179","volume":"96","author":"A Addeo","year":"2021","unstructured":"Addeo, A. et al. Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treat. Rev 96, 102179 (2021).","journal-title":"Cancer Treat. Rev"},{"key":"2172_CR16","doi-asserted-by":"publisher","first-page":"102602","DOI":"10.1016\/j.ctrv.2023.102602","volume":"119","author":"I Attili","year":"2023","unstructured":"Attili, I. et al. Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: a systematic review. Cancer Treat. Rev 119, 102602 (2023).","journal-title":"Cancer Treat. Rev"},{"key":"2172_CR17","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jtho.2024.03.019","volume":"19","author":"L-Y Hu","year":"2024","unstructured":"Hu, L.-Y. et al. EGFR oncogenic mutations in NSCLC impair macrophage phagocytosis and mediate innate immune evasion through up-regulation of CD47. J. Thorac. Oncol. 19, 1186\u20131200 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"2172_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55378-5","volume":"16","author":"B Alsaed","year":"2025","unstructured":"Alsaed, B. et al. Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment. Nat. Commun. 16, 28 (2025).","journal-title":"Nat. Commun."},{"key":"2172_CR19","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1158\/2159-8290.CD-20-1376","volume":"11","author":"LN Gonzalez Castro","year":"2021","unstructured":"Gonzalez Castro, L. N., Tirosh, I. & Suv\u00e0, M. L. Decoding cancer biology one cell at a time. Cancer Discov. 11, 960\u2013970 (2021).","journal-title":"Cancer Discov."},{"key":"2172_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22801-0","volume":"12","author":"F Wu","year":"2021","unstructured":"Wu, F. et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat. Commun. 12, 2540 (2021).","journal-title":"Nat. Commun."},{"key":"2172_CR21","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.7150\/thno.86928","volume":"13","author":"Y Lin","year":"2023","unstructured":"Lin, Y. et al. Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer. Theranostics 13, 4574\u20134600 (2023).","journal-title":"Theranostics"},{"key":"2172_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05831-2","volume":"22","author":"K Li","year":"2024","unstructured":"Li, K., Huang, J., Tan, Y., Sun, J. & Zhou, M. Single-cell and bulk transcriptome analysis reveals tumor cell heterogeneity and underlying molecular program in uveal melanoma. J. Transl. Med. 22, 1020 (2024).","journal-title":"J. Transl. Med."},{"key":"2172_CR23","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1158\/2159-8290.CD-24-1390","volume":"15","author":"X Jiang","year":"2025","unstructured":"Jiang, X. et al. Depletion of effector regulatory T cells associates with major response to induction dual immune checkpoint blockade. Cancer Discov. 15, 1569\u20131592 (2025).","journal-title":"Cancer Discov."},{"key":"2172_CR24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41586-024-08466-x","volume":"639","author":"M Reina-Campos","year":"2025","unstructured":"Reina-Campos, M. et al. Tissue-resident memory CD8 T cell diversity is spatiotemporally imprinted. Nature 639, 483\u2013492 (2025).","journal-title":"Nature"},{"key":"2172_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-101220-015603","volume":"40","author":"SM Downs-Canner","year":"2022","unstructured":"Downs-Canner, S. M., Meier, J., Vincent, B. G. & Serody, J. S. B Cell function in the tumor microenvironment. Annu. Rev. Immunol. 40, 169\u2013193 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"2172_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"2172_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41392-024-02049-y","volume":"9","author":"F Zhang","year":"2024","unstructured":"Zhang, F. et al. Neutrophil diversity and function in health and disease. Signal Transduct. Target. Ther. 9, 343 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2172_CR28","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu, Z. et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell 188, 3081\u20133096 (2025).","journal-title":"Cell"},{"key":"2172_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2025.02.026","volume":"43","author":"H Li","year":"2025","unstructured":"Li, H. et al. Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer Cell 43, 757\u2013775.e8 (2025).","journal-title":"Cancer Cell"},{"key":"2172_CR30","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","volume":"186","author":"F Tang","year":"2023","unstructured":"Tang, F. et al. A pan-cancer single-cell panorama of human natural killer cells. Cell 186, 4235\u20134251.e4220 (2023).","journal-title":"Cell"},{"key":"2172_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","volume":"21","author":"NA Maskalenko","year":"2022","unstructured":"Maskalenko, N. A., Zhigarev, D. & Campbell, K. S. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat. Rev. Drug Discov. 21, 559\u2013577 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2172_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier, E. et al. Natural killer cell therapies. Nature 626, 727\u2013736 (2024).","journal-title":"Nature"},{"key":"2172_CR33","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","volume":"13","author":"A Lisberg","year":"2018","unstructured":"Lisberg, A. et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC. J. Thorac. Oncol. 13, 1138\u20131145 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"2172_CR34","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","volume":"35","author":"S Peters","year":"2017","unstructured":"Peters, S. et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1\u2013selected advanced non\u2013small-cell lung cancer (BIRCH). J. Clin. Oncol. 35, 2781\u20132789 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2172_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","volume":"19","author":"MC Garassino","year":"2018","unstructured":"Garassino, M. C. et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 19, 521\u2013536 (2018).","journal-title":"Lancet Oncol."},{"key":"2172_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02177-7","volume":"23","author":"Y-F Ren","year":"2024","unstructured":"Ren, Y.-F. et al. Single-cell RNA sequencing reveals immune microenvironment niche transitions during the invasive and metastatic processes of ground-glass nodules and part-solid nodules in lung adenocarcinoma. Mol. Cancer 23, 263 (2024).","journal-title":"Mol. Cancer"},{"key":"2172_CR37","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri2154","volume":"7","author":"ND Huntington","year":"2007","unstructured":"Huntington, N. D., Vosshenrich, C. A. J. & Di Santo, J. P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7, 703\u2013714 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"2172_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1600-065X.2006.00451.x","volume":"214","author":"AG Freud","year":"2006","unstructured":"Freud, A. G. & Caligiuri, M. A. Human natural killer cell development. Immunol. Rev. 214, 56\u201372 (2006).","journal-title":"Immunol. Rev."},{"key":"2172_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-021-00824-9","volume":"7","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Integrated single-cell RNA sequencing analysis reveals distinct cellular and transcriptional modules associated with survival in lung cancer. Signal Transduct. Target. Ther. 7, 9 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2172_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16164-1","volume":"11","author":"N Kim","year":"2020","unstructured":"Kim, N. et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat. Commun. 11, 2285 (2020).","journal-title":"Nat. Commun."},{"key":"2172_CR41","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/j.xcrm.2024.101615","volume":"5","author":"C Zhang","year":"2024","unstructured":"Zhang, C. et al. Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE\/CTONG2104). Cell Rep. Med. 5, 101615 (2024).","journal-title":"Cell Rep. Med."},{"key":"2172_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26770-2","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Deciphering cell lineage specification of human lung adenocarcinoma with single-cell RNA sequencing. Nat. Commun. 12, 6500 (2021).","journal-title":"Nat. Commun."},{"key":"2172_CR43","doi-asserted-by":"publisher","first-page":"101489","DOI":"10.1016\/j.xcrm.2024.101489","volume":"5","author":"Y Deng","year":"2024","unstructured":"Deng, Y. et al. Multicellular ecotypes shape progression of lung adenocarcinoma from ground-glass opacity toward advanced stages. Cell Rep. Med. 5, 101489 (2024).","journal-title":"Cell Rep. Med."},{"key":"2172_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1573","volume":"14","author":"L Xie","year":"2024","unstructured":"Xie, L. et al. Spatial transcriptomics reveals heterogeneity of histological subtypes between lepidic and acinar lung adenocarcinoma. Clin. Transl. Med. 14, e1573 (2024).","journal-title":"Clin. Transl. Med."},{"key":"2172_CR45","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.ccell.2022.10.008","volume":"40","author":"S Salcher","year":"2022","unstructured":"Salcher, S. et al. High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer. Cancer Cell 40, 1503\u20131520.e1508 (2022).","journal-title":"Cancer Cell"},{"key":"2172_CR46","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1093\/nar\/gkac781","volume":"50","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Integrated analysis of multimodal single-cell data with structural similarity. Nucleic Acids Res. 50, e121\u2013e121 (2022).","journal-title":"Nucleic Acids Res."},{"key":"2172_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 14, 7 (2013).","journal-title":"BMC Bioinformatics"},{"key":"2172_CR48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","volume":"40","author":"NS Patil","year":"2022","unstructured":"Patil, N. S. et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell 40, 289\u2013300.e284 (2022).","journal-title":"Cancer Cell"},{"key":"2172_CR49","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1016\/j.cell.2024.06.038","volume":"187","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes. Cell 187, 4790\u20134811.e4722 (2024).","journal-title":"Cell"},{"key":"2172_CR50","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e3529 (2021).","journal-title":"Cell"},{"key":"2172_CR51","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/s43018-024-00807-z","volume":"5","author":"X Chu","year":"2024","unstructured":"Chu, X. et al. Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms. Nat. Cancer 5, 1409\u20131426 (2024).","journal-title":"Nat. Cancer"},{"key":"2172_CR52","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/bioinformatics\/btp634","volume":"26","author":"F Li","year":"2009","unstructured":"Li, F. et al. PerturbationAnalyzer: a tool for investigating the effects of concentration perturbation on protein interaction networks. Bioinformatics 26, 275\u2013277 (2009).","journal-title":"Bioinformatics"},{"key":"2172_CR53","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu, Z. et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell 188, 3081\u20133096.e3019 (2025).","journal-title":"Cell"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02172-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02172-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02172-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:01:42Z","timestamp":1767063702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02172-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2172"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-02172-2","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"796"}}